Stock Analysis on Net
AI Tokens
Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

This company has been moved to the archive! The financial data has not been updated since November 7, 2024.

Common-Size Income Statement
Quarterly Data

Moderna Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net product sales 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cost of sales -28.24 -62.50 -57.49 -33.26 -127.55 -249.49 -43.33 -39.47 -35.26 -30.48 -17.16 -13.73 -15.01 -17.87 -11.14 -3.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Gross profit (loss) 71.76% 37.50% 42.51% 66.74% -27.55% -149.49% 56.67% 60.53% 64.74% 69.52% 82.84% 86.27% 84.99% 82.13% 88.86% 96.03% — — — — — — —
Other revenue 2.31 30.98 0.00 0.64 4.21 17.41 1.86 4.63 7.82 4.81 2.38 3.98 3.31 3.74 11.77 185.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Research and development -62.47 -663.59 -636.53 -50.34 -66.02 -391.81 -61.87 -24.92 -26.28 -15.67 -9.35 -9.34 -10.83 -10.03 -23.14 -379.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Selling, general and administrative -15.44 -145.65 -164.07 -16.83 -25.16 -113.31 -16.68 -7.72 -8.91 -4.66 -4.52 -2.90 -3.49 -2.88 -4.44 -39.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income (loss) from operations -3.85% -740.76% -758.08% 0.21% -114.51% -637.20% -20.02% 32.52% 37.37% 54.01% 71.34% 78.01% 73.97% 72.96% 73.05% -137.61% — — — — — — —
Interest income 5.66 60.33 71.86 3.69 5.98 35.49 5.96 1.79 1.86 0.88 0.25 0.10 0.08 0.07 0.23 2.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other income (expense), net -0.66 -14.67 -11.38 -1.40 -2.90 4.78 -2.63 -0.25 -0.22 -0.29 -0.22 -0.10 -0.21 -0.05 -0.58 -0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income (loss) before income taxes 1.15% -695.11% -697.60% 2.51% -111.44% -596.93% -16.68% 34.06% 39.01% 54.60% 71.38% 78.01% 73.85% 72.98% 72.71% -135.59% — — — — — — —
(Provision for) benefit from income taxes -0.44 0.00 -5.99 5.26 -95.16 125.94 21.01 -3.91 -5.58 -6.11 -9.65 -7.82 -4.55 -6.74 -2.25 -0.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Income (loss) 0.71% -695.11% -703.59% 7.77% -206.60% -470.99% 4.32% 30.15% 33.43% 48.49% 61.72% 70.19% 69.29% 66.24% 70.46% -136.33% — — — — — — —

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

The financial performance of the entity exhibits extreme volatility, characterized by a transition from high-margin profitability to significant operational deficits relative to net product sales. The common-size analysis reveals a period of exceptional efficiency between early 2021 and late 2022, followed by a sharp increase in the relative cost of operations and research investments starting in 2023.

Gross Profitability and Cost of Sales
Gross profit margins remained robust from December 2020 through 2022, peaking at 96.03% and gradually declining to 30.15% by December 2022. A severe anomaly occurred in June 2023, where the cost of sales reached 249.49% of net product sales, resulting in a gross loss of 149.49%. This indicates a period where the direct costs of production significantly exceeded the revenue generated from sales. A recovery trend is observed in late 2024, with the gross profit margin returning to 71.76% by September 30, 2024.
Operating Expense Trends
Research and development (R&D) and selling, general, and administrative (SG&A) expenses have shown disproportionate growth relative to sales. R&D spending, which hovered between 9% and 26% of sales during 2021, escalated dramatically in 2023 and 2024, reaching a peak of 663.59% of net product sales in June 2024. Similarly, SG&A expenses spiked to 164.07% of sales in March 2024. These patterns suggest a strategic shift toward heavy investment in pipeline development and infrastructure despite a contraction in product revenue.
Operating and Net Income Volatility
The operating margin transitioned from a peak of 78.01% in September 2021 to deep deficits, notably reaching -740.76% in June 2024. The net income mirrors this instability, swinging from a high of 70.46% in March 2021 to a loss of 703.59% in March 2024. The severe losses in 2023 and 2024 are primarily driven by the surge in operating expenses relative to the shrinking scale of net product sales.
Non-Operating Income Influence
Interest income has become an increasingly significant component of the financial structure. While negligible in 2021, interest income as a percentage of net product sales rose sharply in early 2024, reaching 71.86% in March and 60.33% in June. This suggests that the entity is relying heavily on its cash reserves and investment returns to offset substantial operating losses during the current transition phase.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?